Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe page’s revision label was updated from v3.6.2 to v3.6.3, indicating a small update to the document or template rather than a change to trial information.SummaryDifference0.1%

- Check11 days agoChange DetectedThe page's revision tag was updated to v3.6.2, replacing the previous v3.6.0 and indicating a refreshed page version.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRecruitment status on the study page was updated to indicate that no more participants are being sought. At the same time, the page adds new navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and logs a new Revision: v3.6.0, while older labels such as Intervention / Treatment and Revision: v3.5.5 were removed.SummaryDifference0.5%

- Check32 days agoChange DetectedThe page shows a revision update from v3.5.4 to v3.5.5, indicating a minor backend or UI update without changing the study details.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page now shows revision v3.5.4 instead of v3.5.3, representing a newer version of the record and a metadata refresh rather than a substantive change to the study details.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page’s UI/build “Revision” marker was updated from v3.5.2 to v3.5.3. This reflects a platform version change rather than an update to the trial details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.